Antibody persistence of two pentavalent DTwP–HB–Hib vaccines to the age of 15–18 months, and response to the booster dose of quadrivalent DTwP–Hib vaccine

Sharma, Hitt; Yadav, Sangeeta; Lalwani, Sanjay; Kapre, Subhash V.; Jadhav, Suresh; Parekh, Sameer; Palkar, Sonali; Ravetkar, Satish; Bahl, Sunil; Kumar, Rakesh; Shewale, Sunil

doi:10.1016/j.vaccine.2012.11.038

Cited by 15 publications

(25 citation statements)

References 10 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Consistent with previous studies [ 13 , 14 , 15 , 16 , 17 , 18 , 19 , 20 ], the GMTs of IgG-PT were low, significantly higher in children 19–36 months of age: 17.78 IU/ml versus in children 37–55 months of age: 14.79 IU/ml. Twenty-five (25.64%) subjects had titers >25 IU/ml, significantly higher in children 19–36 months of age.…”

Section: Discussionsupporting

confidence: 91%

“…In Algeria in 2008, the SII vaccine (DTwP) was replaced by the Sanofi Pasteur vaccine (DTwP Hib). However, no sero epidemiological studies were performed after the change of vaccine although it is known that immunogenicity of vaccine containing wP vaccines can vary [ 14 , 15 , 16 ].…”

Section: Discussionmentioning

confidence: 99%

“…The high rate of fully protected subjects against diphtheria had previously demonstrated by other studies. Indeed, these studies showed that 100% of children had DT antibody titers ≥0.1 IU/ml as well as in children who received the combined SII or Sanofi Pasteur vaccine [ 16 , 25 ]. Only five subjects had basic protection (<0.1 IU/ml) and need immediate booster.…”

Section: Discussionmentioning

confidence: 99%

See 2 more Smart Citations

Immune responses to vaccine-preventable diseases among toddlers and preschool children after primary immunization and first booster in Northwestern Algiers, Algeria

Benamrouche

Maamar

Chemli

et al. 2018

Heliyon

View full text Add to dashboard Cite

ObjectivesTo determine immune responses to selected vaccine-preventable communicable diseases: pertussis, diphtheria and Haemophilus influenzae type b (Hib1) in Algerian toddlers and preschool children after primary vaccination and first booster, recruited from three local healthcare facilities in Northwestern Algiers.MethodsThe information of demographic characteristics and vaccination status were collected for each subject by questionnaire. Specific antibody levels and Hib antibody avidity were determined using commercial ELISA kits.ResultsA total of eighty-one subjects aged between 19 and 55 months were studied. Almost all subjects were fully protected against diphtheria (76/81; 93.83%; 95% CI2: 86.35–97.33) and invasive Hib disease (29/30; 96.67%; 95% CI: 83.33–99.41), while only 20/78 (25.64%; 95% CI: 17.26–36.31) had anti-PT3 (pertussis toxin) antibody levels above 25 IU/ml. A significant decrease of anti-PT antibody levels was observed until the age of 36 months (p = 0.02). GMTs4 (geometric mean titers) of anti-PT antibodies were low, but remain significantly higher in children ≤36 months of age (p = 0.02). Both GMT and rates of ≥0.15 μg/ml, ≥1 μg/ml, and ≥5 μg/ml titers were significantly higher in Hib-vaccinated subjects (p < 0.01). Relative Hib-avidity index (≥50%) and GMAI5 (geometric mean avidity index) were high in both Hib-vaccinated and -unvaccinated groups.ConclusionsAs shown in the present study, young children were fully protected against diphtheria and Hib, but showed low immunity to pertussis. Further sero-epidemiological studies including a large number of subjects with a wider range of age are needed to explore the immunity level in older children, adolescents and adults.

show abstract

Section: Discussionsupporting

confidence: 91%

Section: Discussionmentioning

confidence: 99%

Section: Discussionmentioning

confidence: 99%

See 1 more Smart Citation

Immune responses to vaccine-preventable diseases among toddlers and preschool children after primary immunization and first booster in Northwestern Algiers, Algeria

Benamrouche

Maamar

Chemli

et al. 2018

Heliyon

View full text Add to dashboard Cite

show abstract

“…Although more than 90% of children had detectable antibodies against diphtheria and tetanus, only 55.7% of children had protective anti-diphtheria and 85.2% protective anti-tetanus antibodies. After full vaccination, protection against tetanus and diphtheria has been shown to normally exceed 90% [10,11]. Median anti-tetanus and anti-diphtheria levels should be 2 to 4 times higher than observed in the present study [12,13].…”

Section: Discussionmentioning

confidence: 48%

Low and disparate seroprotection after pentavalent childhood vaccination in the Lao People's Democratic Republic: a cross-sectional study

Evdokimov

Sayasinh

Nouanthong³

et al. 2017

Clinical Microbiology and Infection

View full text Add to dashboard Cite

After a full documented course of vaccination, seroprotective rates were unusually low and disparate against components of the pentavalent vaccine. These can only partially be explained by the negative predictors identified. Although many children had been infected, only few were chronic carriers of HBsAg. Our study demonstrates an urgent need to monitor the serologic response to vaccination, particularly in resource-poor countries.

show abstract

“…It remains to be determined whether the differences detected at this vaccine dose correlate with different clinical efficacies. In children, immunogenicity and safety studies produced 99% response to wP for Quinvaxem and approximately 78% for Pentavac and Easyfive, but no human efficacy data are available at this time [22,23].…”

Section: Discussionmentioning

confidence: 99%

The mouse intranasal challenge model for potency testing of whole-cell pertussis vaccines

Queenan

Fernandez

Shang

et al. 2014

Expert Review of Vaccines

View full text Add to dashboard Cite

The mouse nasopharyngeal challenge model could be considered as a potency and release assay for wP vaccines. Whether this model directly correlates with clinical vaccine efficacy requires further investigations. Whether this model directly correlates with clinical vaccine efficacy requires further investigations. The mouse nasopharyngeal challenge model could be considered as a potency and release assay for wP vaccines.

show abstract

Antibody persistence of two pentavalent DTwP–HB–Hib vaccines to the age of 15–18 months, and response to the booster dose of quadrivalent DTwP–Hib vaccine

Cited by 15 publications

References 10 publications

Immune responses to vaccine-preventable diseases among toddlers and preschool children after primary immunization and first booster in Northwestern Algiers, Algeria

Immune responses to vaccine-preventable diseases among toddlers and preschool children after primary immunization and first booster in Northwestern Algiers, Algeria

Low and disparate seroprotection after pentavalent childhood vaccination in the Lao People's Democratic Republic: a cross-sectional study

The mouse intranasal challenge model for potency testing of whole-cell pertussis vaccines

Contact Info

Product

Resources

About